PORTFOLIO
Investing in Novel Technologies That Could Shape the Future of Healthcare
Leal Therapeutics is a biotechnology company dedicated to developing novel precision medicines for patients with high-need central nervous system disorders.
Hyku Biosciences is developing small-molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression.
UK-based company
Currently operating in stealth mode.
Stylus Medicine is developing in vivo genetic medicines to unlock cures. The company’s platform is powered by engineered recombinases that encode therapeutics with high precision.
Dualitas Therapeutics is pioneering the future of bispecific antibody therapies. Driven by its DualScreen discovery engine, Dualitas is advancing novel bispecific antibody therapies for immunological and inflammatory disease.
Repertoire Immune Medicines is discovering the unique immune codes that determine how we maintain health and respond to disease. Repertoire’s proprietary DECODE™ platform uniquely elucidates the entire immune synapse, providing a comprehensive understanding of the interactions between T cell receptors and their cognate antigenic epitopes.
Ten63 is an advanced AI drug-discovery company that was a Duke and TTIC spin-out, headquartered in the Research Triangle in North Carolina. Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. The company is advancing an internal oncology pipeline while pursuing select, strategic partnerships across multiple indications.